Wolf A M
The Women's Place and Health Evaluation Science Department, University of Virginia Health System, Charlottesville 22908, USA.
Obes Res. 1998 Apr;6 Suppl 1:2S-7S. doi: 10.1002/j.1550-8528.1998.tb00682.x.
From both societal and payer perspectives, the economic effect of obesity in the United States is substantial, estimated at approximately 6% of our national health expenditure and cost of care in a major health maintenance organization. The number of physician visits related to obesity has increased 88% in a 6-year period. The morbidity cost (lost productivity) and functional capability of the patient with obesity is increasing rapidly (50% increase in lost productivity, 36% increase in restricted activity, and 28% increase in number of bed-days). Cost savings of treating obesity are comparable to those of treating other chronic diseases such as coronary heart disease and diabetes. Most studies indicate that most of the direct health care costs of obesity are from type 2 diabetes, coronary heart disease and hypertension. To date, however, there have been no published reports of the cost effectiveness of the medical management of obesity treatment. In conclusion, the cost of obesity is comparable to that of other chronic diseases, yet it receives disproportionately less attention. Cost effectiveness studies need to be initiated promptly.
从社会和支付方的角度来看，肥胖在美国造成的经济影响巨大，据估计约占我国国民医疗支出以及一家大型健康维护组织护理成本的6%。与肥胖相关的医生诊疗次数在6年时间里增加了88%。肥胖患者的发病成本（生产力损失）和功能能力正在迅速上升（生产力损失增加50%，活动受限增加36%，住院天数增加28%）。治疗肥胖症的成本节约与治疗其他慢性疾病（如冠心病和糖尿病）相当。大多数研究表明，肥胖症的大部分直接医疗成本来自2型糖尿病、冠心病和高血压。然而，迄今为止，尚无关于肥胖症治疗的药物管理成本效益的公开报告。总之，肥胖症的成本与其他慢性疾病相当，但受到的关注却少得不成比例。成本效益研究需要立即启动。
